InspireMD (NYSE:NSPR) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of InspireMD (NYSE:NSPR) in a research report sent to investors on Wednesday morning. The brokerage issued a sell rating on the stock.

Separately, Lake Street Capital started coverage on InspireMD in a research report on Wednesday, December 11th. They set a “buy” rating and a $5.00 target price on the stock.

InspireMD Price Performance

InspireMD stock opened at $2.68 on Wednesday. InspireMD has a 12-month low of $1.81 and a 12-month high of $3.80. The company has a market capitalization of $79.57 million, a price-to-earnings ratio of -3.57 and a beta of 0.88. The firm’s fifty day moving average price is $2.86 and its 200 day moving average price is $2.76.

Institutional Investors Weigh In On InspireMD

Hedge funds and other institutional investors have recently modified their holdings of the stock. Renaissance Technologies LLC bought a new stake in shares of InspireMD in the 4th quarter valued at approximately $27,000. Legato Capital Management LLC acquired a new position in InspireMD in the fourth quarter worth $47,000. Schonfeld Strategic Advisors LLC increased its stake in InspireMD by 153.2% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 30,133 shares of the company’s stock valued at $79,000 after purchasing an additional 18,233 shares during the last quarter. Northern Trust Corp raised its holdings in shares of InspireMD by 103.7% during the fourth quarter. Northern Trust Corp now owns 48,022 shares of the company’s stock worth $126,000 after purchasing an additional 24,452 shares during the period. Finally, Essex Investment Management Co. LLC bought a new position in shares of InspireMD in the 4th quarter worth about $191,000. Institutional investors own 44.78% of the company’s stock.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.